{"entity":{"id":"amit-oza","kind":"person","name":"Amit M. Oza","aka":[],"tldr":"Amit Oza is a gynaecologic oncologist who led early olaparib and niraparib studies in ovarian cancer.","summary":"Amit M. Oza is Head of the Division of Medical Oncology and Hematology and Director of the Cancer Clinical Research Unit at the Princess Margaret Cancer Centre. He is a gynaecologic oncologist known for leading early olaparib and niraparib studies that established PARP inhibition in BRCA-mutant and platinum-sensitive ovarian cancer. His selected paper reports a randomised phase 2 trial of olaparib combined with chemotherapy in recurrent platinum-sensitive ovarian cancer. He now heads medical oncology at Princess Margaret and continues to lead gynaecologic trials in ovarian and endometrial cancer.","asOf":"2026-09-08","links":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/amit-m-oza"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oza%20AM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["olaparib","niraparib"],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit","institutionId":"princess-margaret","specialisms":["Ovarian cancer","PARP inhibitors","Gynaecologic trials"],"profiles":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/amit-m-oza"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oza%20AM%5BAuthor%5D"}],"papers":[{"title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","journal":"Lancet Oncology","year":2015,"url":"https://doi.org/10.1016/S1470-2045(14)71135-0","doi":"10.1016/S1470-2045(14)71135-0"},{"title":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1810858","doi":"10.1056/NEJMoa1810858"}]},"route":"/people/amit-oza/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","route":"/institutions/princess-margaret/"}],"paper":[{"id":"paper-solo-1-nejm-2018","kind":"paper","name":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","route":"/key-papers/paper-solo-1-nejm-2018/"}]}}